Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Xi Jinping faces stiffest challenge to rule as Covid outrage sparks mass protests
    • China rocked by protests as zero-Covid anger spreads
    • Global inflation likely to have peaked, key data indicators suggest
    • Shanghai protests: ‘We want everyone to hear our voice’
    • Xi Jinping’s ‘myth of infallibility’ tested as zero-Covid protests rattle China
  • US
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Finance staff ignoring mandatory office attendance demands, report suggests
    • Qatari owners of Paris Saint-Germain target valuation of over €4bn
    • Nervous auditors re-examine crypto clients after FTX collapse
    • Barclays chief to undergo treatment for cancer
    • Rolls-Royce tests hydrogen-fueled aircraft engine in aviation world first
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • The week that could unravel the global oil market
    • Live news updates: UK retailers face ‘little festive cheer’ as outlook darkens
    • Nervous auditors re-examine crypto clients after FTX collapse
    • Crypto lender BlockFi files for Chapter 11 bankruptcy
    • Miami nightclubs mourn absence of high-rolling crypto entrepreneurs
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • The UK government should stop doing stupid stuff
    • The Great Unretirement is coming
    • Get ready for a net zero business backlash
    • China’s zero-Covid protests create a rare nationwide coalition of interests
    • Xi Jinping’s pandemic triumphalism returns to haunt him
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Privacy at work and the rise of the ‘quiet space’
    • Science Museum’s Ian Blatchford: ‘If the arts world is not careful, it will be eaten alive by its own piety’
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Notting Hill hip? How the west was (re)won
    • Investor Howard Marks: ‘The short run is by far the least important thing’
    • In the court of Mar-a-Lago, ‘King’ Trump still reigns supreme
    • Best books of 2022: FT critics’ picks
    • How to design your kitchen like a professional chef
  • HTSI
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Hannah Kuchler

Global Pharmaceuticals Correspondent
Hannah Kuchler reports on the pharmaceutical industry and the Covid-19 pandemic. She previously covered US pharma and biotech in New York and the technology industry in Silicon Valley.
Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)
Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Sunday, 27 November, 2022
    Medical science
    Team behind Apple’s Face ID develops tiny robots to deliver drugs into brain

    Bionaut Labs has raised $43.2mn in second financing round to fund first clinical trials

  • Monday, 21 November, 2022
    News in-depthHealthcare
    Big Pharma targets $50bn obesity drugs market as demand booms

    Eli Lilly seeks approval for weight loss medication as Novo Nordisk battles supply crunch for Wegovy

  • Friday, 18 November, 2022
    Autumn Statement
    UK tech founders and science chiefs attack chancellor’s R&D tax raid

    Jeremy Hunt made the levy relief, seen as a lifeline for small companies, less generous in the Autumn Statement

  • Thursday, 10 November, 2022
    ReviewNon-Fiction
    The Song of the Cell by Siddhartha Mukherjee — what makes our cells tick?

    A gripping exploration of the science of the body raises profound moral questions

  • Thursday, 10 November, 2022
    AstraZeneca PLC
    AstraZeneca drops submission to US regulators for Covid-19 vaccine approval

    Plan abandoned almost two years after initial approval in UK and Europe

  • Tuesday, 8 November, 2022
    Covid-19 vaccines
    Patent wars: Moderna’s battle for the spoils of Covid vaccines

    Ending of pharma group’s IP truce spells fight for future of mRNA technology

  • Monday, 31 October, 2022
    Biotech
    Biotechs look to sell royalties to raise cash in a tough market

    Companies look for alternative sources of funds after share sell-off

  • Wednesday, 26 October, 2022
    Biotech
    Investors hunt for biotech bargains as market shows signs of a thaw

    Valuations soared in the pandemic and then crashed, but more promising start-ups are managing to raise funds

  • Tuesday, 18 October, 2022
    ReviewNon-Fiction
    The Long Shot — Kate Bingham on Britain’s Covid vaccine rollout

    The head of the UK’s vaccine procurement tells the inside story of the risks, criticism and political interference she faced

  • Tuesday, 18 October, 2022
    Roche Holding AG
    Roche’s sales of Covid drugs fall by $1bn

    Swiss pharma group says demand for coronavirus tests dropped as severity of virus ebbed

  • Thursday, 13 October, 2022
    GSK PLC
    GSK hails respiratory virus jab after trial results

    Drugmaker says new RSV shot appears more effective than rival Pfizer’s candidate

  • Sunday, 21 August, 2022
    The Big Read
    Randox: the next test for the UK government’s favourite diagnostics firm

    The company that made hundreds of millions from Covid-19 contracts wants to normalise private health testing

  • Saturday, 20 August, 2022
    Covid-19 vaccines
    GSK vaccine chief aims to break dominance of mRNA shots

    Group developing jab with Sanofi that could have benefits

  • Friday, 19 August, 2022
    News in-depthBiotech
    Revolutionary Crispr gene editing speeds from lab to treatment room

    The first drug to make use of technology discovered only a decade ago will be with regulators by the end of the year

  • Tuesday, 16 August, 2022
    AstraZeneca PLC
    AstraZeneca sues former executive over move to rival GSK

    Pharma group alleges breach of non-compete agreement to delay start date of departing business development official

  • Monday, 15 August, 2022
    Covid-19 vaccines
    UK becomes first country to approve Omicron-specific Covid booster

    Moderna’s two-strain shot will target both the original strain and BA.1 in step with European regulators

  • Sunday, 14 August, 2022
    The Big Read
    How science is getting closer to a world without animal testing

    New technology involving miniature human organs built in a lab is a step towards better treatments and ending a contentious practice

  • Friday, 12 August, 2022
    NHS England
    NHS England to increase beds and call handlers as winter crisis looms

    Push to create equivalent of 7,000 extra beds and boost recruitment follows testing summer for health service

  • Thursday, 11 August, 2022
    Pharmaceuticals sector
    Pharma groups lose £30bn of value on heartburn drug lawsuit worries

    Companies face thousands of pending personal injury cases linking Zantac to cancer

  • Monday, 8 August, 2022
    Covid-19 vaccines
    BioNTech and Pfizer to begin vaccine clinical trial for new Covid variants

    German biotech aims for ‘prolonged and broad protection’ as sales and earnings miss expectations

  • Saturday, 30 July, 2022
    AstraZeneca PLC
    AstraZeneca to double number of countries where US biotech arm sells rare disease drugs

    Anglo-Swedish pharmaceutical group wants to capitalise on its $39bn acquisition of Alexion

  • Friday, 29 July, 2022
    AstraZeneca PLC
    AstraZeneca raises forecasts after strong Covid and cancer drug sales

    Chief executive says revenue rise will allow drugmaker to boost investment in R&D

  • Wednesday, 27 July, 2022
    GSK PLC
    GSK raises profit guidance after strong sales of shingles vaccine

    Quarterly figures beat expectations as pharma group strengthens pipeline of new drugs

  • Thursday, 21 July, 2022
    Joe Biden
    Joe Biden has contracted Covid, White House says

    US president has ‘very mild symptoms’ and is taking Pfizer antiviral pill

  • Wednesday, 20 July, 2022
    Biotech
    Cambridge biotech Abcam to abandon London listing for Nasdaq

    Further blow to UK stock market comes despite government’s efforts to promote life sciences

Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
    • US Midterm Elections
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In